Inactivation of CYP2D6 by Berberrubine and the Chemical Mechanism

被引:0
|
作者
Rao, Jinqiu [1 ,2 ,3 ]
Wang, Tianwang [1 ,2 ,3 ]
Yu, Leran [1 ]
Wang, Kai [1 ,2 ]
Qiu, Feng [1 ,2 ,3 ]
机构
[1] Tianjin Univ Tradit Chinese Med, Sch Chinese Mat Med, Tianjin 301617, Peoples R China
[2] Tianjin Univ Tradit Chinese Med, Tianjin Key Lab Therapeut Subst Tradit Chinese Med, Tianjin 301617, Peoples R China
[3] Tianjin Univ Tradit Chinese Med, State Key Lab Component Based Chinese Med, Tianjin 301617, Peoples R China
基金
中国国家自然科学基金;
关键词
IN-VITRO; DRUG-INTERACTIONS; METABOLISM; BERBERINE; INHIBITION; PHARMACOKINETICS; BUPROPION; RELEVANCE; P450;
D O I
10.1021/acs.biochem.4c00450
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Berberrubine (BRB), belonging to the benzylisoquinoline alkaloid, is a main metabolite of berberine in vivo. BRB was previously proven to undergo metabolic activation mediated by P450s. In this study, the chemical interactions between BRB and CYP2D6 enzyme were investigated. First, a variety of P450s participated in the metabolism of berberine transformed to BRB, but CYP2D6 was the most involved enzyme. A time-, concentration-, and nicotinamide adenine dinucleotide phosphate (NADPH)-dependent inhibition of CYP2D6 was caused by BRB. The inhibitory effect of BRB on CYP2D6 was irreversible. The maximum reaction rate constants of inactivation (k inact) and half-maximal inactivation (K I) of BRB on CYP2D6 were 0.0410 min-1 and 3.798 mu M, respectively. Metoprolol, a classic substrate of CYP2D6, attenuated CYP2D6 from inactivation by BRB. Glutathione (GSH) and catalase/superoxide dismutase failed to protect against the inactivation of CYP2D6 caused by BRB. Three cys-based adducts derived from the reaction of electrophilic metabolites of BRB with CYP2D6 were detected by ultra performance liquid chromatography-mass spectrometry (UPLC-MS)/MS. The reactive metabolites derived from BRB might be responsible for the inactivation of CYP2D6. In summary, BRB was characterized as a mechanism-based inactivator of CYP2D6.
引用
收藏
页码:3078 / 3089
页数:12
相关论文
共 50 条
  • [41] Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics
    Saiz-Rodriguez, Miriam
    Ochoa, Dolores
    Roman, Manuel
    Zubiaur, Pablo
    Koller, Dora
    Mejia, Gina
    Abad-Santos, Francisco
    PHARMACOGENOMICS, 2020, 21 (10) : 663 - 675
  • [42] CYP2D6 Genotype Phenotype Discordance Due to Drug-Drug Interaction
    Monte, Andrew A.
    West, Kelsey
    McDaniel, Kyle T.
    Flaten, Hania K.
    Saben, Jessica
    Shelton, Shelby
    Abdelmawla, Farah
    Bushman, Lane R.
    Williamson, Kayla
    Abbott, Diana
    Anderson, Peter L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (05) : 933 - 939
  • [43] Combining Antidepressants with β-Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction
    Shin, Jaekyu
    Hills, Nancy K.
    Finley, Patrick R.
    PHARMACOTHERAPY, 2020, 40 (06): : 507 - 516
  • [44] Effect of the CYP2D6*10 allele on the pharmacokinetics of clomiphene and its active metabolites
    Kim, Mi-Jung
    Byeon, Ji-Yeong
    Kim, Young-Hoon
    Kim, Se-Hyung
    Lee, Choong-Min
    Jung, Eui Hyun
    Chae, Won Ki
    Lee, Yun Jeong
    Jang, Choon-Gon
    Lee, Seok-Yong
    Choi, Chang-Ik
    ARCHIVES OF PHARMACAL RESEARCH, 2018, 41 (03) : 347 - 353
  • [45] In vitro Inhibition of Human CYP1A2, CYP2D6, and CYP3A4 by Six Herbs Commonly Used in Pregnancy
    Langhammer, Astrid Jordet
    Nilsen, Odd Georg
    PHYTOTHERAPY RESEARCH, 2014, 28 (04) : 603 - 610
  • [46] In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation
    Sager, Jennifer E.
    Tripathy, Sasmita
    Price, Lauren S. L.
    Nath, Abhinav
    Chang, Justine
    Stephenson-Famy, Alyssa
    Isoherranen, Nina
    BIOCHEMICAL PHARMACOLOGY, 2017, 123 : 85 - 96
  • [47] Impact of CYP2D6*2A, CYP2D6*4 and CYP3A5*3 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients
    Okda, Sherouk M.
    El-Bassiouny, Noha A.
    El Amrawy, Ahmed Mahmoud
    Salahuddin, Ahmad
    Elonsy, Sohila M.
    Kassem, Amira B.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (10) : 2539 - 2553
  • [48] A Comprehensive CYP2D6 Drug-Drug-Gene Interaction Network for Application in Precision Dosing and Drug Development
    Ruedesheim, Simeon
    Loer, Helena Leonie Hanae
    Feick, Denise
    Marok, Fatima Zahra
    Fuhr, Laura Maria
    Selzer, Dominik
    Teutonico, Donato
    Schneider, Annika R. P.
    Solodenko, Juri
    Frechen, Sebastian
    van Der Lee, Maaike
    Moes, Dirk Jan A. R.
    Swen, Jesse J.
    Schwab, Matthias
    Lehr, Thorsten
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025,
  • [49] Cannabidiol, a Major Phytocannabinoid, As a Potent Atypical Inhibitor for CYP2D6
    Yamaori, Satoshi
    Okamoto, Yasuka
    Yamamoto, Ikuo
    Watanabe, Kazuhito
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (11) : 2049 - 2056
  • [50] How to Integrate CYP2D6 Phenoconversion into Clinical Pharmacogenetics: A Tutorial
    Cicali, Emily J.
    Elchynski, Amanda L.
    Cook, Kelsey J.
    Houder, John T.
    Thomas, Cameron D.
    Smith, D. Max
    Elsey, Amanda
    Johnson, Julie A.
    Cavallari, Larisa H.
    Wiisanen, Kristin
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (03) : 677 - 687